How much does gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?

Prostate

Volumn 67, Issue 15, 2007, Pages 1614-1620

  Choo, R ^a,b   Danjoux, C ^b   Morton, G ^b   Szumacher, E ^b   Sugar, L ^b   Gardner, S ^b   Kim, M ^b   Choo, C M ^b   Klotz, L ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Follow up biopsy; Histologic grade change; Prostate cancer; Surveillance alone

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER LOCALIZATION; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SCORING SYSTEM; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 35648970584     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20648     Document Type: Article

References (6)

1. Epstein JI, Walsh PC, Carter BH. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001;166(5):1688-1691.
2. Cumming JA, Ritchie AW, Goodman CM, McIntyre MA, Chisholm GD. Dedifferentiation with time in prostate cancer and the influence of treatment on the course of the disease. Br J Urol 1990;65(3):271-274.
3. Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol 2004;11:2118-2124.
4. Choo R, Klotz L, Danjoux C, Morton G, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: Watchful observation of localized, low to intermediate grade, prostate carcinoma with selective delayed intervention based on PSA, histologic and/or clinical progression. J Urol 2002;167:1664-1669.
5. Choo R, Klotz L, DeBoer G, Danjoux C, Morton G. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int 2004;94:295-298.
6. Epstein J, Walsh P, Sauvageot J, Carter B. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997;158:1886-1890.